Chinese venture capital investment in US biotech companies fell by more than half in the first half of the year as Washington tightened scrutiny of funding from overseas, raising fears that US start-ups will struggle to raise funds and access the large Chinese market.
由于美国政府收紧对海外资金的审查，今年上半年，manbetx3.0 风险资本对美国生物科技公司的投资下降了一半以上，这促使人们担忧美国初创企业将难以融资以及难以进入庞大的manbetx3.0 市场。
您已阅读7%（350字），剩余93%（4593字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。